Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT04262856. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.
Study identification
- NCT ID
- NCT04262856
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 151 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 28, 2020 (Actual)
- Primary completion
- Jul 9, 2025 (Actual)
- Completion
- Jul 9, 2025 (Actual)
- Last update posted
- Jun 15, 2026
2020 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Innovative Clinical Research Institute (ICRI) | Whittier | California | 90603 | — |
| Florida Cancer Specialists | Englewood | Florida | 34223 | — |
| Florida Cancer Specialists | Gainesville | Florida | 32605 | — |
| Florida Cancer Specialists - Panhandle | Tallahassee | Florida | 32308 | — |
| Florida Cancer Specialists - East | West Palm Beach | Florida | 33401 | — |
| Baptist Health Lexington | Lexington | Kentucky | 40503 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion | Ridgewood | New Jersey | 07450 | — |
| Clinical Research Alliance | Lake Success | New York | 11042 | — |
| Northwell Health Cancer Institute | Lake Success | New York | 11042 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| Allegheny General Hospital (AGH)-Alleghney Singer Research Institute | Pittsburgh | Pennsylvania | 15224 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| The Center For Cancer And Blood Disorders (Texas Cancer Care) | Fort Worth | Texas | 76104 | — |
| Millennium Oncology | Houston | Texas | 77339 | — |
| Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care | Blacksburg | Virginia | 24060 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04262856, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 15, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04262856 live on ClinicalTrials.gov.